The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

PBC is a rare and chronic liver disease that disproportionately affects women. The condition causes the small bile ducts in ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

Deaths caused by this disease more than tripled between 2017 to 2019 and it is now the fastest rising cause of cancer deaths ...

Non-alcoholic fatty liver disease (NAFLD) has emerged as a growing concern in liver cancer development. This condition, often ...

Experts warn that fatty liver disease (FLD) is becoming an epidemic in India, driven by genetics and lifestyle. With a ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Learn how personalised treatments are providing new hope with tailored therapies offering better outcomes for patients ...

Bilirubin, the byproduct of hemoprotein breakdown, particularly hemoglobin, is a critical marker in diagnosing, prognosing, ...

hepatic ischemia-reperfusion injury (HIRI), and chronic conditions like nonalcoholic fatty liver disease (NAFLD) and ...

Liver cancer deaths more than tripled between 2017 and 2019 and the disease is now the fastest rising cause of cancer deaths ...